For postmenopausal women with hormone
receptor-positive metastatic breast cancer with
disease progression following antiestrogen therapy

FASLODEX® (fulvestrant) Injection treatment for postmenopausal women with hormone receptor-positive metastatic breast cancer with disease progression following antiestrogen therapy
See FASLODEX® (fulvestrant) Injection efficacy data from the CONFIRM trial

Prolonged Progression-free Survival Data and Updated Overall Survival (OS) Analysis

See the updated OS analysis
from the CONFIRM trial